Small Immunotherapy Drug Trial Sees 100% Success Rate For All Participants
Dostarlimab Trial for Newly Diagnosed Stage II/III Mismatch Repair Deficient (dMMR)/High Microsatellite Instability (MSH-H) Rectal Cancer
WHAT EVERYONE IS TALKING ABOUT!
A small but impressive immunotherapy drug (dostarlimab) trial of stage II or III rectal cancer patients whose tumors had dMMR (mismatch repair-deficient)/high microsatellite instability (MSI-H) at Memorial Sloan Kettering Cancer Center.
Lynch Syndrome carriers rejoice! This may be a game changer for us!!!
dMMR/MSI-H are hallmarks of LS related colorectal cancer tumors
100% of the first consecutive 14 patients’ cancer tumors disappeared!!
100% of the trial participants have remained cancer free for up to 2 years!!
A larger group of patients and longer follow-up is needed to assess if these results can be replicated and how long cancer free duration will remain.
Why is this trial so important:
Normally these patients would face treatment with chemo, radiation and life-altering surgery with possible permanent side effects such as infertility, urinary, sexual and bowel dysfunction, or the possibility of a permanent ostomy bag.
No serious adverse reactions of the drug were observed allowing patients to live their lives without the harsh effects that chemo, radiation and surgery cause.
Most immunotherapy trials have been conducted after previous cancer treatments have been tried and the cancer has spread (stage IV-metastatic). Maybe treating cancer with immunotherapy before it has a chance to spread is more effective.
New important questions remain:
Could this therapy work on patients who are high risk (such as LS carriers) before a cancer even develops?
Could this alter the course of how to treat cancer and redefine anti-cancer therapies?
Learn More:
https://www.simplemost.com/cancer-disappears-patients-small-drug-trial/